SinuNase

Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis

TAMPA, Fla.--(BUSINESS WIRE)--Jun 28, 2007 - Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) announced on Wednesday, June 27 at the Jefferies Healthcare Conference that its interim analysis of the blinded data on the first fifty patients in the Fast-Tracked Phase 3 clinical study of SinuNase(TM), ...

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

...ts who believe they may be eligible to participate in a clinical trial with sinunase are encouraged to visit www.accentia.net/patients/trials_sinunase.php, or c... is under clinical development to treat chronic sinusitis (rhinosinusitis). sinunase is a novel application and formulation of a known anti-fungal exclusively l...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

...ies. The Company's lead product candidate is SinuNase(TM), a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. sinunase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans...

SinuNase in Biological News

SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma

...proximately twice the size of asthma, there is currently no approved prescription pharmaceutical available for treatment of the disease. If approved, sinunase will be the first therapy available to treat sufferers of CS. Accentia Biopharmaceuticals is commercializing SinuTest for the confirmation of CS. Inv...